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Abstract  
Cytotoxicity of ochratoxin A (OTA) was evaluated using the MTS assay, and membrane 
integrity was measured using transepithelial electrical resistance (TEER). A transwell 
system was used to investigate the effect of OTA on the expression of the CYP450 (1A1, 
2A6, 2B6, 3A4 and 3A5), NAT2, COX-2, LOX-5, and MRP2 genes in Caco-2 and HepG2 
cells. TEER decreased by a mean of 63.2% after 24 h in Caco-2 differentiated cells 
without inducing cell detachment; revealing damage to the intestinal epithelial cell tight 
junction proteins and an increase in cell permeability. Gene expression analysis showed 
that modulation of gene expression by OTA was higher in Caco-2 cells than in HepG2 
cells, and generally, the duration of exposure to OTA had a more significant effect than 
the OTA dose. A general OTA down-regulation effect was observed in Caco-2 cells, in 
contrast with the down- and up-regulation observed in HepG2 cells. In Caco-2 cells, 
CYP1A1 was the gene with the highest regulation, followed by CYP3A4 and CYP3A5. 
Conversely, in HepG2 cells, CYP2B6 was highly regulated at 3 and 12 h compared to 
the other cytochromes; CYP1A1 was slightly modulated during the first 12 hours, but an 
overexpression was observed at 24 hours. 
Our data support the involvement of the COX-2 and 5-LOX genes in liver metabolism of 
OTA. On the basis of the gene expression analysis, the results suggest a possible 
impairment in OTA secretion at the intestinal and hepatic level due to MRP2 repression. 
In addition, we provide evidence of the effect of OTA on NAT2 gene expression, which 
had not been reported before. 
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1. Introduction  
Ochratoxin A (OTA) is a mycotoxin produced by some species of two ubiquitous genera 
of fungi, Aspergillus and Penicillium. This mycotoxin is frequently found in a wide variety 
of raw materials (such as cereals and fruits) and foodstuffs (coffee, beer, wine, cocoa 
products, and grape juice) (EFSA, 2006). It can also be found in foods of an animal 
origin due to its bioaccumulation in tissues, even in the case of animals sub-chronically 
exposed to OTA (Perši et al., 2014). The presence of OTA in feed has been linked to the 
development of nephrotoxicity, which, in rats, has been associated with renal adenomas 
and kidney tumours (Boorman, 1989; IARC, 1993). Several mechanisms of OTA toxicity 
have been described, including competition with phenylalanine for protein synthesis, 
inhibition of mitochondrial ATP production, production of free radicals, promotion of lipid 
peroxidation, and direct and indirect damage to DNA (El Khoury and Atoui, 2010; 
González-Arias et al., 2014; Ringot et al., 2006). 
OTA is absorbed in the intestine, where the multi-drug resistance protein 2 (MRP2 gene) 
plays an important role acting as a xenobiotic outward transporter to reduce the oral 
bioavailability and the toxin load to organs and, thereby, OTA toxicity (Berger et al., 2003; 
Dietrich et al., 2003). Once OTA reaches the bloodstream, it can reach other organs 
such as the liver, and the MRP2 transporter is again a key primary active transporter 
involved in anionic conjugate and drug/xenobiotic extrusion into the extracellular space, 
which contributes to bile formation and the subsequent elimination of the toxin (Dietrich 
et al., 2003; Jedlitschky et al., 2006). 
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The inactivation or bioactivation of the OTA molecule via the cytochrome P450 system 
has been described as a key factor in relation to the in vitro and in vivo OTA toxicity. 
For example, Zepnil et al. (2001) showed that OTA oxidation was mediated by the 
CYP450 enzymes in in vitro reactions with microsomes of liver and kidney from Wistar 
rats. On the other hand, Pfohl-Leszkowicz et al. (2012) have demonstrated the formation 
of OTA-derived DNA adducts and mutations and the involvement of the CYP450 
enzymes in the bioactivation of OTA. The presence of DNA double-strand breaks and the 
micronucleus formation observed in in vivo or in vitro assays with cells capable of 
expressing cytochrome P450 (CYP450) enzymes support the OTA genotoxicity 
(González-Arias et al., 2014; Groene et al., 1996; Hibi et al., 2013).  
Little is known about the involvement of human N-acetyltransferase 2 (NAT2), a phase II 
enzyme encoded by the NAT2 gene. NAT2 shows a restricted tissue distribution, and 
high levels are found in the human liver and intestine. Lack of NAT2 function is 
associated with higher incidences of cancer and drug toxicity (Husain et al., 2007). To 
our knowledge, the study of Lebrun et al. (2002) is the only one that has analysed the 
involvement of NAT2 in OTA genotoxicity. The authors observed a positive correlation 
between DNA damage and NAT2 polymorphisms in human urothelial cells exposed to 
OTA. 
Regarding the cyclooxygenase-2 (COX-2) and lipoxygenase-5 (5-LOX) genes, some in 
vitro and in vivo assays indicate that the over expression of these genes is related to 
cancer initiation or chronic inflammation processes in a variety of cancers in humans. For 
this reason, both genes have been described as inflammatory mediators (González-
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Périz and Clàira, 2007; Terzic et al., 2010), but the modulation of these genes by OTA is 
still poorly studied (Ferrante et al., 2006; Kumar et al., 2013; Ramyaa et al., 2014).  
The present study aimed to investigate the effect of OTA on expression of five genes 
from the CYP450 family (CYP1A1, CYP2A6, CYP2B6, CYP3A4 and CYP3A5), as well 
as expression of the NAT2, COX-2, 5-LOX and MRP2 genes. Although the involvement 
of the CYP450 enzymes is well known in OTA biotransformation, much less is known 
about the role of COX-2, 5-LOX and NAT2 and the effect of OTA in the modulation of 
expression of these genes. Considering that OTA is a mycotoxin that mainly enters the 
human body via ingestion, we have used an in vitro cell co-culture system to mimic initial 
passage through the intestine and hepatic metabolism, using two human cell lines. Caco-
2 cell line is a well established in vitro model especially indicated to study intestinal 
absorption, metabolism, and bioavailability of drugs and xenobiotics (Artursson et al., 
2001; Natoli et al., 2011). On the other hand, the use of human liver cells, as the HepG2 
cell line, in the co-culture system tries to simulate the place where the main xenobiotic 
metabolism occurs in humans. 
2. Methodology  
2.1 Reagents and instrumentations  
The following products were obtained from Sigma-Aldrich (Steinheim, Germany): OTA 
standard (98% purity) (ref. O1877), non-essential amino acids (ref. M7145), L-glutamine 
(ref. G7513), antibiotic mixture (penicillin and streptomycin) (ref. P4333, dimethyl 
sulfoxide (DMSO) (ref. D8418), and oligonucleotide primers (Table 1). Foetal bovine 
serum (ref. FB1090500) was supplied by BioSera (Nauille, France). TRIzoI® (ref. 15596) 
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reagent, ethidium bromide (EtBr) (ref. 15585011), TURBOTM DNase (Ambion) (ref. 
AM2238), SuperScriptTM III reverse transcriptase (ref. 18080) and Oligo(dT)12-18 
primer (ref. 18418-012) were obtained from Gibco BRL Life Technologies (Grand Island, 
NY, USA). Dulbecco’s modified Eagle medium (DMEM) (ref. SH30022) and a solution of 
trypsin-EDTA (0.25%, 0.2 g/L) (ref. SH30042) were obtained from Thermo Fisher 
(Madrid, Spain). iTaqTM Universal SYBR® Green Supermix (ref. 172-5124) and the Hard-
Shell® 96-Well Thin-Wall PCR (ref.6340589) Plates were obtained from Bio-Rad 
(Hercules, CA, USA). 75 cm2 flasks (ref. 156499) and 96-well plates (ref. 267313) were 
supplied by Nunc (Roskilde, Denmark). 6-transwell systems (4.67 cm2 and 0.4 µm 
polycarbonate pore size insert) and 6-well plates were obtained from Corning (ref. 3526) 
(New York, USA). The CellTiter 96® Aqueous One Solution Cell Proliferation Assay (ref. 
G3582) was obtained from Promega (Madison WI, USA). 
 
2.2 Cell culture 
The human colon cell line Caco-2 (HTB-37) and the hepatic cell line HepG2 (HB-8065) 
were obtained from the American Type Culture Collection (ATCC). Cells were grown as 
monolayer cultures in 75 cm2 flasks and maintained with DMEM in an atmosphere at 
95% relative humidity and 5% CO2 at 37 °C. DMEM was supplemented with foetal 
bovine serum (15% v/v for Caco-2 or 10% v/v for HepG2 cells), 1% (v/v) of non-essential 
amino acids, 1% (v/v) of L-glutamine and 1% (v/v) of an antibiotic mixture (penicillin and 
streptomycin). Cellular monolayers (80% confluence) were detached with a solution of 
trypsin-EDTA, and the cells were reseeded to carry out the cytotoxicity assay or the co-
5 
culture system. Caco-2 and HepG2 cells were used at passages from 33 to 42 and from 
15 to 25, respectively. 
 
2.3 Cytotoxic assays  
2.3.1 MTS assay  
HepG2 cells were reseeded in 96-well plates at a density of 1.5 x 105 cells/cm2, and 
Caco-2 cells were reseeded at a density of 105 cells/cm2, allowing 24 h for cell 
adherence. Cell viability was determined using a stable solution of MTS from the 
CellTiter 96® Aqueous One Solution Cell Proliferation Assay. OTA doses tested were 1, 
5, 15, 45, 60, 75, 90 and 180 μM (in DMSO) for 3, 12 and 24 h. The treatments were 
conducted in cell culture medium, and the percentage of DMSO in the treatments was 
0.05% of the final volume. At the end of the treatment, cells were washed once with PBS. 
Immediately, 100 μL of culture medium with 317 μg/mL MTS-one solution was added per 
well. Cells were incubated for 2.5 h (Caco-2) or 2 h (HepG2). Optical density was 
determined using a 96-plate reader (DAS-A3, Roma, Italy) with a 490 nm filter (FGF2, 
TSP1). Relative cell viability was expressed as a percentage with respect to the cells in 
the solvent control treatment. 
 
2.3.2 Transepithelial electrical resistance (TEER) measurement 
The maintenance of cell monolayers was performed as described in the co-culture 
section. The TEER value of all of the Caco-2 cell monolayers was recorded at day 21 
(before treatments) to determine the effect of OTA on membrane integrity as a 
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cytotoxicity parameter. TEER recordings were made using a Millicell-ERS electrical 
resistance system (Millipore Ibérica, Spain) with a STX01 electrode (Millipore Ibérica, 
Spain), according to the manufacturer´s instructions. Values are expressed as Ω•cm2, 
according to the equation 1: 
TEERmonolayer = (Resistancemonolayer-Resistanceblank)·(filter growth area in cm2)  equation 1 
Resistanceblank is considered as the value of the resistance of a filter without cells. 
 
2.4 Caco-2/HepG2 co-culture system 
2.4.1 Caco-2 differentiation 
Caco-2 cells were reseeded at 105 cells/cm2 on polycarbonate membrane inserts in 6-
transwell plates and maintained for 21 days with complete medium. The TEER increment 
was monitored at 9, 15 and 20 days (3 wells for each experiment) as a signal of 
progression of cell differentiation. The TEER increase (mean ± DS) was in the range of 
240 ± 20 to 500 ± 35 Ω•cm2. 
 
2.4.2 Co-culture system and OTA treatments 
The transwell permeable supports were used for transepithelial electrical resistance 
(TEER) and the gene expression studies. HepG2 cells were seeded in 6-well plates at a 
density of 1.5 x 105 cells/cm2 (at day 20 of the Caco-2 cells differentiated monolayers). 
Twenty-four hours after the seeding of HepG2 cells, the co-cultures were performed 
(Day 21). Non-cytotoxic doses (5, 15 and 45 μM) of OTA were selected for 3, 12 and 24 
h treatments in transwell plates. The treatments were carried out in culture medium, and 
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the percentage of solvent (DMSO) in the treatments was 0.05% of the final volume in the 
transwell system for all of the treatments. 
 
2.5 Gene expression  
2.5.1. RNA extraction and cDNA synthesis 
Total RNA was prepared from freshly isolated cells using the Trizol® reagent, according 
to the manufacturer´s protocol. RNA integrity was checked on an agarose gel stained 
with ethidium bromide (EtBr). The concentration and purity of total RNA were determined 
by measuring the ratio of absorbance at 260/280 nm and 260/230 nm in a NanoDrop 
ND-1000 (Thermo Scientific, USA), respectively. 5 µg of total RNA was treated with 
TURBOTM DNase to remove contaminating genomic DNA. The SuperScriptTM III reverse 
transcriptase kit and a Oligo(dT) primer were used to synthesize first-strand cDNA. 
 
2.5.2. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
Primers used in this study are listed in Table 1. The primer set used for amplifying the 
CYP2A6 gene was designed with OLIGO Primer Analysis Software V.7. Real-time RT-
qPCR reactions were performed in a CFX96 Touch™ Real-Time PCR Detection System 
(Bio-Rad Laboratories, Hercules, CA, USA) monitoring cDNA amplification with iTaqTM 
Universal SYBR® green Supermix (Bio-Rad Laboratories, Hercules, CA, USA). The 
program included one cycle at 95 ºC for 2 minutes followed by 40 cycles of 15 s at 95 ºC 
and 30 s at 58 ºC and, finally, a dissociation and amplification curve step to check the 
PCR reaction quality. 
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To validate the RT-qPCR, a standard curve was generated with 6 set points of two-fold 
serial cDNA dilutions. A pool of cDNA from Caco-2 or HepG2 cells was used to run the 
standard curve. The standard curve was generated by plotting the quantification cycle 
(Cq) versus the logarithmic value of the cDNA concentration. The real-time PCR 
efficiency (E) of one cycle in the exponential phase was calculated for each primer pair 
(equation 2), where the slope belongs to the standard curve (Rasmussen, 2001). 
 
E = 10[-1/slope]                equation 2 
 
Expression level was normalized using glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) mRNA. The relative expression ratio (r) of the genes was calculated according 
to the 2-ΔΔCp mathematical model, based on E and the Cq deviation (equation 3) (Pfaffl, 
2001). 
 
r = (Etarget)∆CPtarget  / (Ereference)∆CPreference       equation 3 
 
ΔCqtarget is the subtraction of Cqcontrol from the Cqsample for the target gene, and 
ΔCqreference is the subtraction of Cqcontrol from the Cqsample for the reference gene.  
 
[Insert Table 1 in this place, if possible]  
 
2.7 Statistics 
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Three experiments were run in triplicate, and each sample was run twice (technical 
replicates) for the gene expression analysis. Each value represents the mean ± SE. 
Statistical analyses were conducted using Statgraphics plus. Cell viability, membrane 
integrity and gene expression were analysed using ANOVA and the Bonferroni post-test. 
p-values < 0.05 were considered to be statistically significant. 
 
3. Results  
3.1 Cytotoxic assays  
3.1.1 MTS assay  
The increase of OTA concentration (from 1 to 180 µM) resulted in a significant decrease 
of cell viability in both cell types, at the three exposure times assayed (Table 2), 
measured by the metabolic reduction of MTS tetrazolium compound. This became more 
evident in the 24 h treatment, where cell viability was reduced from 80.6 to 53.8% (Caco-
2 cells) and from 87.8 to 66.3% (HepG2 cells) between the two extreme values of OTA 
concentration tested. Based on the results of the viability assay, three non-cytotoxic OTA 
concentrations (5, 15 and 45 µM) were chosen for the membrane integrity and gene 
expression assays (> 70 % viability for both cell types). 
 
[Insert Table 2 in this place, if possible]   
 
3.1.2 Membrane integrity  
TEER measurement is useful to detect changes in physiological barrier function caused 
by the assayed compounds. In particular, TEER reflects the transepithelial permeability 
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of water-soluble ions. The integrity of the Caco-2 cell monolayer was markedly and 
significantly affected after OTA treatments (5, 15 and 45 OTA µM) with the longest 
exposition time. Table 3 shows the TEER values at 3, 12 and 24 h. The 3 or 12 h 
treatments showed a slight, but significant, decrease in TEER values. The observed 
decreases in TEER, expressed as a percentage of the value at 24 h of treatment, were 
63.6%, 61.5% and 64.6% (at 5, 15 and 45 µM OTA treatments, respectively), which 
means an increase in permeability without cell detachment. The solvent (DMSO) had no 
significant effect on the TEER-values (p > 0.05) compared to the monolayer exposed to 
culture medium alone (data not shown). 
 
[Insert Table 3 in this place, if possible] 
 
3.2 Gene expression 
To elucidate OTA metabolism, gene expression of the CYP450 family (CYP1A1, 
CYP2A6, CYP2B6, CYP3A4 and CYP3A5), the inflammatory markers COX-2 and 5-
LOX, the xenobiotic metabolizer NAT2, and the MRP2 transporter was analysed in a co-
culture system of Caco-2 and HepG2 cells. It should be firstly noted that gene 
expression was not affected by the added solvent (DMSO) as there were no statistically 
significant differences between the blank (medium alone) and DMSO treatments, with a 
p-value of 0.6882 for the Caco-2 cells and 0.3128 for the HepG2 cells. Hence, all relative 
gene expression ratios were calculated by referring to the Cp-values from the control 
treatments that were exposed to the same DMSO concentration as the OTA treatments. 
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CYP2A6 expression was not detected in mRNA samples from HepG2 cells. Details of 
the statistical analysis of treatment (OTA concentration and time exposure) effects on 
gene expression in both Caco-2 and HepG2 cells are shown in Figures 1 and 2, 
respectively. 
The gene expression analysis shows that when Caco-2 cells were treated with 
increasing amounts of OTA, expression of most of the analysed genes was down-
regulated (Figure 1). Among the CYP450 family, CYP1A1 was the gene with the highest 
down-regulation, with statistical significance for the three treatments and different 
exposure times (p < 0.0001). CYP1A1 expression was greatly reduced by OTA within the 
first 3 h; however, the highest effect of OTA was observed after 12 h, with a 52-fold 
decrease in CYP1A1 gene expression. Interestingly, cells exposed for 24 h showed a 
much lower repression of CYP1A1, compared with the mean-value of cells treated for 12 
h. 
According to our results, OTA had an effect on the expression level within the first 3 
hours, but we did not detect large changes in the expression level of the CYP2A6 and 
CYP2B6 genes. It is known that CYP3A4 is a very active gene in the presence of 
endogenous substrates and xenobiotics. Under our conditions, we obtained an 
unexpected result for the level of CYP3A4 expression, showing a very stable level during 
the 3 first hours and poor modulation by OTA compared to the results with CYP1A1 and 
NAT2. Increasing OTA concentrations did not cause a significant difference in the 
expression of CYP3A4 in cells treated for 3 and 12 h. At 24 h, only the treatment with 45 
µM caused a significant difference (p = 0.0396) with regard to 5 and 15 µM OTA. A 
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similar expression pattern was observed in CYP3A5, but the down-regulation was 
slightly higher. 
Interestingly, NAT2, of which there is limited information regarding its interaction with 
OTA, was the gene with the second largest down-regulation during 12 and 24 h of 
exposure (p < 0.0001). Expression levels of the inflammation markers, COX-2 and 5-
LOX, were also decreased. The presence of OTA caused a larger regulation of COX-2 
than 5-LOX. Additionally, the higher effect on COX-2 (45 µM for 24 h) shows a greater 
statistical significance (p = 0.0003). Finally, in general, the down-regulation was more 
pronounced in Caco-2 cells at 24 h and 45 µM OTA. 
 
[Insert Figure 1 in this place, if possible] 
 
Regarding the results of the hepatic cells, OTA induced both up- and down-regulation 
(Figure 2). Unlike the results obtained in Caco-2 cells, CYP3A4 expression increased 
significantly after 12 h exposure to OTA (p < 0.05), regarding the results at 3 h of 
exposure. In this case, CYP3A5 was down-regulated by OTA at 45 µM, but after 12 h 
only showed a slight response to OTA exposure at 5 and 15 µM. 
The CYP1A1 expression level results obtained with HepG2 cells showed a significant 
change with respect to other CYPs analysed, which is very different to the strong down-
regulation observed in Caco-2 cells. CYP1A1 was slightly down-regulated by OTA at 12 
h, but a significant increase was detected in the cells exposed for 24 h (p = 0.00258 
compared to 12 h). The CYP2B6 gene was down-regulated within the first 3 h, whereas 
an up-regulation effect was observed after 12 h exposure with a statistically significant 
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difference (p = 0.002). However, after 24 h, CYP2B6 expression once again decreased 
in cells exposed to 15 and 45 µM OTA. 
The NAT2 gene showed a different response at 24 h compared to 3 and 12 h. This gene 
increased its expression after a longer OTA exposure in the HepG2 cells, in contrast to 
what happens in Caco-2 cells. With respect to the inflammation markers, these genes 
were slightly modulated by OTA at 3 h of treatment; both COX-2 and 5-LOX genes 
appeared to be up-regulated within the first 12 h. However, at 24 h, COX-2 maintained its 
expression level, but 5-LOX was down-regulated. Unlike Caco-2 cells, in HepG2 cells, 
the MRP2 transporter showed a slight but significant down-regulated response (p < 0.05) 
after treatments at 15 and 45 µM OTA for 12 and 24 h. 
 
[Insert Figure 2 in this place, if possible] 
 
4. Discussion 
The first OTA evaluation conducted by the IARC (IARC, 1983) concluded that the 
evidence for nephrotoxicity, teratogenicity and carcinogenicity was insufficient to classify 
OTA as a carcinogenic compound to humans. Later, the toxic potential of OTA was 
greatly supported. However, the toxicological mechanism of this mycotoxin is still 
unclear, and a controversy exists about its genotoxic or epigenetic mode of action (IARC, 
1993; Marin-Kuan et al., 2006). Kinetics studies in animal species showed that OTA is 
slowly distributed to peripheral compartments (Galtier et al. 1979, Sreemannarayana et 
al., 1988; Li et al., 1997), and that the molecule could be reabsorbed and redistributed 
(Hagelberg et al., 1989; Fuchs and Hult, 1992; Sreemannarayana et al., 1988). Several 
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studies have reported a prolonged half-life of the toxin and a secondary reintroduction to 
the intestine through the enterohepatic circulation, since the biliary excretion of OTA is 
very efficient, making the presence of OTA in the intestine prolonged in time (Li et al., 
1997; Ringot et al., 2006). OTA toxicity has been attributed to its isocoumarin moiety, and 
it is well known that OTA is inactivated/bioactivated by cytochrome P450 enzymes 
(Faucet-Marquis et al., 2006; Malaveille et al., 1991; Ringot et al., 2006; Tozlovanu et al., 
2012). 
In order to observe the change induced in vitro by OTA over time, and taking into 
account the high half-life and the enterohepatic circulation of OTA observed in in vivo 
studies, in the present study the toxicity and the effect on gene expression of OTA were 
assayed at three times of exposure (3, 12 and 24 h). To carry out our study we have 
used a co-culture system with Caco-2 and HepG2 cells that mimics the absorption in the 
intestine (through of the porous membrane) and the hepatic metabolism. 
In this system, the effect of OTA on the expression of cytochrome genes, the NAT2 gene 
(involved in phase II of metabolism), two inflammation markers (COX-2 and 5-LOX) and 
the MRP2 gene (encoding for a transporter of xenobiotics outward during absorption and 
in liver metabolism) was evaluated. 
 
The cell viability results from the MTS assay showed that only 24 h of OTA exposure 
caused a decrease in viability. Our data agree with other studies which also described 
high viability percentages (low cytotoxicity values) in treatments with <100 µM OTA for 24 
h or less (Berger et al., 2003; Maresca et al., 2001; McLaughlin et al., 2004; Sergent et 
al., 2005; Ramyaa et al., 2013). Similarly, other authors obtained viabilities of 75% (HT-
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29-D4) and 80% (in Caco-2 cells) at 48 h (Maresca et al., 2001; McLaughlin et al., 2004), 
using low OTA concentrations (20 µM and 30 µM) in the case of Caco-2 cells. Different 
results were reported by Zheng et al. (2013), who found that 37.27 µM OTA for 24 h 
caused 50% cytotoxicity in HepG2 cells. 
In addition, OTA cytotoxicity was also determined by evaluating membrane integrity in 
Caco-2 cells. Our results showed that OTA caused damage in physiological barrier 
functions through a paracellular transport that decreases TEER. This mechanism 
involves substances up to 10 but not 20 kDa, as OTA, and the elimination of tight 
junction proteins (Claudin 3 and 4). Conversely, good membrane homeostasis is related 
to high TEER and the presence of tight junctions (Kiatsurayanon et al., 2014; Yuki et al., 
2007). 
In Caco-2 cells, membrane integrity (measured by TEER) and cell viability (from the MTS 
assay) were closely related. In this study, we found a decrease of 60% in TEER 
(disruption of the paracellular barrier) and a significant loss of viability when Caco-2 cells 
were treated with 45 µM OTA for 24 h. Maresca et al. (2001) recorded a decrease of 
50% in TEER after a treatment of 100 µM OTA for 48 h that was related to a decrease in 
the whole cellular protein content, the inhibition of growth cell and morphological 
changes. In our assay (5-45 µM for 24 h) as well as Maresca et al. (2001) (0.001-1 µM 
for 48 h), we did not record a decrease of TEER in a time-dependent manner, possibly 
due to the low range of OTA doses assayed. Conversely, McLaughlin et al. (2004), with 
higher OTA doses (20-160 µM for 5 to 25 h), recorded a time-dependent reduction in 
TEER. Studies evaluating TEER during short-term exposures and at low OTA 
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concentrations, did not detect a significant decrease of TEER in Caco-2 cells, as found 
by Berger et al. (2003), using 10 µM OTA for 3 h, or in our study during the 3 h treatment. 
To further investigate the effect of OTA on the xenobiotic transporter gene (MRP2), the 
metabolic enzymes (cytochrome P450: CYP1A1, CYP2A6, CYP2B6, CYP3A4 and 
CYP3A5; and NAT2), and the inflammatory response genes (COX-2 and 5-LOX), a gene 
expression analysis was performed using Caco-2 and HepG2 cells. Our data showed a 
down-regulation of MRP2 expression, indicating an impairment of the secretion of OTA. 
The MRP2 transporter is a key primary active transporter involved in anionic conjugate 
and drug extrusion from the human liver but which is also present in the apical 
membranes of enterocytes, kidney-proximal tubules and other cells (Jedlitschky et al., 
2006). In rat, it has been observed that OTA was excreted 15% less in the proximal 
tubules of the kidney, while the proximal tubular transport of amino acids was not 
impaired by OTA (Gekle and Silbernagl, 1994). Therefore, the down-regulation of MRP2 
and the TEER decrease found in this study could be the mechanism through which OTA 
reaches high percentages of bioavailability in vivo. In this way, the OTA exposure in 
hepatic cells would be magnified, contributing to the hepatotoxicity. Considering the 
nephrotoxic potential of OTA, the down-regulation of the MRP2 gene may also have a 
major impact on the proximal tubule, leading to a decreased capacity to eliminate OTA. 
However, further studies are needed on the OTA transporter mechanism to corroborate 
this hypothesis. 
Concerning the expression of the CYP450 genes, these genes were down-regulated and 
up-regulated by OTA in Caco-2 and HepG2 cells, respectively. The induction of CYP450 
genes in the xenobiotic response has been previously studied, and the mechanism is 
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now largely understood. Nevertheless, the mechanism involved in CYP450 suppression 
still remains to be clarified. The CYP450 genes show a similar response because they 
often involve activation of common cytosolic or nuclear receptors, including the aromatic 
hydrocarbon receptor, the constitutive androstane receptor, the pregnane X receptor, and 
the peroxisome proliferator-activated receptor-alpha (Honkakoski and Negishi, 2000). 
The effect of polycyclic and halogenated aromatic hydrocarbons is used as model for 
understanding the mechanisms of CYP450 suppression, and the results of OTA-
modulation gene expression in the present study show both effects, up- and down 
regulation mainly on HepG2 cells. The literature suggests that the down-regulation is a 
response to physiological and pathological signals: a) stress signals caused by toxicants 
and inflammation, b) an adaptive response, allowing controlled generation of reactive 
oxygen species (ROS), nitric oxide, or arachidonic acid metabolism, or c) a collateral 
response after controlling a physiological pathway (Morgan, 2001). 
In agreement with our results with OTA-treated hepatocytes, in which there was an 
increase in gene expression (mainly 1A1, 2B6 and 3A4 in HepG2 cells), Zepnik et al. 
(2001) reported an increase of OTA hydrolysis by microsomal enzymes from rat liver, 
specifically for P450 3A1/2, 3A4 and P450 1A1/2. In terms of gene expression, Ayed-
Boussema et al. (2012) described an up-regulation of expression levels in all 
cytochromes assayed (CYP3A4, 2B6, 3A5, and 2C9) in a primary human hepatocyte 
culture. CYP3A4 mRNA did significantly increase after OTA treatment at 0.1 μM (from 
3.1- to 16.7-fold induction, respective of each donor). In contrast, Marin-Kuan et al. 
(2006) showed a slight but predominant effect of down-regulation (> 56% of the genes) 
in the liver and kidney from male Fisher-344 rats. In Dark Agouti rats of both sexes, only 
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CYP3A4 expression was detected in male livers after OTA treatment, and CYP1A 
expression was higher than CYP2A (Pfohl-Leszkowicz et al., 1998), as in our in vitro 
assay. 
With regard to CYP2B6, our results at 5-45 µM OTA for 3 h showed a down-regulation up 
to 8-fold in both cell types, but an increase was detected at 12 h in HepG2 cells. In 
contrast with the up-regulation of CYP2B6 in primary human hepatocytes, the level of 
CYP2B6 mRNA was higher (22.5-6.8-fold induction) than the mRNA level of other 
cytochromes after treatment at 10 μM (Ayed-Boussema et al., 2012). 
NAT2 gene, encoding for an inducible and xenobiotic metabolizing enzyme of phase II, 
had lower expression in Caco-2 cells than in HepG2 cells, in line with results described 
in the literature (Husain et al., 2007). In our study, the highest effect on NAT-2 expression 
was detected after 24 h of OTA exposure, where the NAT2 gene was strongly modulated 
by OTA. It is noteworthy that expression of the NAT2 gene regarding OTA exposure has 
not been studied previously, although Lebrun et al. (2002) reported a high correlation 
between NAT2 polymorphism and DNA damage in an in vitro culture of OTA-exposed 
human urothelial cells. OTA intake has been linked to a chronic tubulointerstitial renal 
disease (chronic nephropathy) frequently accompanied by urothelial cell carcinomas of 
the urinary tract, although this relationship has not been proven completely (Batuman, 
2006; Grollman and Jelacovic, 2007; Reddy and Bhoola, 2010). Besides, a very strong 
epidemiological association has been established between the NAT2 genotypes and a 
variable risk of urinary bladder cancer caused by arylamines, possibly due to an impaired 
detoxification of carcinogenic metabolites in the liver (Hein et al., 2000; Husain et al., 
2007). 
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To investigate modulation of the inflammatory response induced by OTA, the expression 
of COX-2 and 5-LOX genes was determined. We have detected a rapid change from 3 to 
12 h in cellular 5-LOX expression in Caco-2 cells, while in HepG2 cells, the changes 
were over time. The COX-2 gene was down- and up-regulated in Caco-2 and HepG2 
cells, respectively. Changes in the regulation pattern could be due to an adaptive 
response (Chung et al., 2008; Morgan, 2001). 
Changes in the regulation pattern could be due to an adaptive response for controlling 
the generation of ROS, as observed by Chung et al. (2008) in A549 human lung 
carcinoma cells treated with acenaphthenequinone. In this sense, the oxidative stress 
caused by OTA has been widely described in the literature as ROS generation (Ramyaa 
et al. 2013), DNA damage (González-Arias et al., 2014; Ramyaa et al., 2013) and 
histopathological changes in the liver and kidney (Aydin et al., 2003). Recently, Kumar et 
al. (2013) and Ramyaa et al. (2013) investigated the relationship between OTA exposure 
and COX-2 expression and obtained similar results as our study. Thus, in mouse (with a 
single dermal application of OTA), an early inflammatory response, demonstrated by 
COX-2 expression, increased after 6 h of OTA exposure and a maximum was observed 
at 18 h (Kumar et al., 2013). Ramyaa et al. (2013) observed that COX-2 expression 
increased after 15 h exposure to OTA in HepG2 cells, but, curiously, it was inhibited after 
24 h. In the present study, we have not studied NF-κB expression, but several studies 
indicate that the expression of COX-2 and 5-LOX is related to NF-κB, the main 
transcription factor that regulates the proinflammatory response (González-Périz and 
Clàira, 2007; Chung et al., 2008). Nowadays, few studies have investigated the effect of 
OTA on the COX-2 and 5-LOX genes, or on their proteins (Ramyaa et al., 2014; Kumar 
20 
et al., 2013; Ferrante et al., 2006 and 2008), and a possible mechanism of down-
regulation has not been established. Some authors have observed an inhibition of 
nuclear factor-kappa B (NF-κB) expression and an increase in heat shock protein 72 
expression, both in in vivo and in vitro studies, after OTA exposure, leading the down-
regulation of proinflammatory mediators (Ferrante et al., 2006, Ramyaa et al., 2014). Our 
results support previous studies which described a pro-inflammatory role of OTA but 
further studies are necessary. 
 
5. Conclusion  
The use of cell lines is an alternative to overcome the disadvantages of the primary cell 
lines, as their scarce availability, limited growth potential, short lifespan, differences 
between batches, and their susceptibility to undergo early and variable phenotypic 
alterations. Additionally, basal gene expression in freshly isolated primary human cells is 
also different between culture passages (Hart et al., 2010). The proper use of data 
published in literature can support the results and the focus of our study. However, 
depending on the human cell line or primary cell line used, and its ability to express or 
induce the genes, comparison of results can be difficult. In addition, an increase in the 
mRNA level in cells or liver tissues does not necessarily mean that similar results occur 
at protein level (Hart et al., 2010; Sun et al., 2002).  It is known that different processes 
are implicated in OTA metabolism and toxicity. Direct or indirect DNA damage, as well as 
epigenetic mechanisms, are responsible for the tumour promotion phase during 
carcinogenesis, and all of these mechanisms have been related to OTA toxicity at non-
cytotoxic doses during long-term exposure (Gonzalez-Arias et al., 2014; Horvath et al., 
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2002; Qi et al., 2014). Conversely, histological changes in the liver, kidney and skin have 
been detected after high doses of OTA exposure (Kamp et al., 2005; Kumar et al., 2013; 
Palabiyik et al., 2013; Qi et al., 2014). The co-culture system that mimics the passage 
through the intestine as a first barrier allowed us to obtain results that could be more 
similar than those recorded in in vivo studies. The data generated from the gene 
expression analysis in enterocytes and hepatocytes exposed to OTA suggest a different 
mechanism of action in intestinal epithelium during absorption than in OTA metabolism in 
the liver. 
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Table 1. Primers used for the analysis of gene expression by RT-qPCR 
Target 
gen 
Forward (F)  
Reverse (R) 
Primer sequence (5´-3´) Length 
(bp) 
Primer reference 
CYP1A1 F TTCCGACACTCTTCCTTCGT 20 
Ayed-Boussema et al. 
(2012) 
  R ATGGTTAGCCCATAGATGGG 20   
CYP2A6 F ACCCCAGTTTCTTCTCCAACCC 22  This study (*) 
  R CCGAAACAGTTCCGCTTTCCGAT 23   
CYP2B6 F GGCCATCGGGAGCCCTTG 18 
Ayed-Boussema et al. 
(2012) 
  R AGGGCCCCCTTGGATTTCCG 20   
CYP3A4 F GCCTGGTGCTCCTCTATCTA 20 
Ayed-Boussema et al. 
(2012) 
  R GGCTGTTGACCATCATAAAAG 21   
CYP3A5 F TGACCCAAAGTACTGGACAG 20 
Ayed-Boussema et al. 
(2012) 
  R TGAAGAAGTCCTTGCGTGTC 20   
COX-2 F CAAATCCTTGCTGTTCCCACCCAT 24 
Rasheed and Haqqi, 
(2012) 
  R GTGCACTGTGTTTGGAGTGGGTTT 24   
5-LOX F ACCACGGAGATGGTAGAGTGCAG 23 Zhou et al. (2007) 
  R GCAGCTCAAAGTCCACGATGAA 22   
NAT2 F ACGTCTCCAACATCTTCATTTATAACC 27 Kocabas et al. (2004) 
  R TCAACCTCTTCCTCAGTGAGAGTTTTA 27   
MRP2 F ACAGAGGCTGGTGGCAACC 19 Pascolo et al. (2003) 
  R ACCATTACCTTGTCACTGTCCATGA 25   
GAPDH F TGCACCACCAACTGCTTAGG 20 Vreeburg et al. (2011) 
  R GGCATGGACTGTGGTCATGAG 21   
(*):sequence designed with with OLIGO Primer Analysis Software V.7. (accession number 
NM_000762.5). 
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Table 2. Relative viability (%) determined by the MTS test in cells treated with OTA (1-
180 µM) for 3, 12 and 24 hours (n=9). 
  Relative viability (%)   
Cells OTA (µM) 3 hours 12 hours 24 hours 
Caco-2 1 106.78 ± 1.75a 100.43 ± 5.14a 80.57 ± 3.55a 
 5 106.87 ± 3.75a 97.96 ± 3.01a 78.37 ± 3.34a 
 15 102.60 ± 2.98a 96.80 ± 2.46a 72.17 ± 3.50ab 
 45 107.08 ± 2.37a 86.18 ± 1.21a 76.14 ± 8.23bc 
 60 99.18 ± 3.01a 90.99 ± 2.70ab 74.00 ± 6.34bc 
 75 104.36 ± 2.61a 95.50 ± 6.78b 66.26 ± 3.57bc 
 90 99.55 ± 3.75a 91.15 ± 2.47b 60.44 ± 4.03c* 
 180 87.01 ± 3.76b 84.98 ± 4.72b 53.81 ± 4.35d 
p-value  0.0072 0.0012 <0.0001 
     
HepG2 1 98.53 ± 0.48a 97.48 ± 2.65a 87.75 ± 1.66ab 
 5 97.34 ± 2.83a 101.38 ± 2.71a 91.06 ± 1.50a 
 15 91.81 ± 2.02ab 101.73 ± 3.42a 85.58 ± 1.30ab 
 45 98.44±  2.24a 101.86 ± 3.43a 91.53 ± 2.04a 
 60 95.97 ± 2.54ab 100.87 ± 2.16a 90.66 ± 2.04ab 
 75 95.55 ± 2.81ab 103.97 ± 3.84a 88.43 ± 2.06ab 
 90 88.98 ± 2.06ab 98.34 ± 2.75a 88.64 ± 1.51ab 
 180 81.58 ± 2.37c 83.74 ± 2.20c 66.28 ± 2.21c 
p-value  0.0001 0.0001 <0.0001 
Relative viability was calculated regarding solvent control (0.05% DMSO). Mean ± SE 
values followed by the same letter within an exposure time are not significantly different 
(p > 0.05). Statistical analysis was performed for each kind of cells separately. *(n=7). 
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Table 3. Effect of OTA on the transepithelial electrical resistance (TEER) in differentiated 
monolayers of Caco-2 cells. 
 TEER Ω•cm2 (Mean ± SE) 
OTA (µM) 3 hours 12 hours 24 hours p-value 
5 503.50 ± 5.68a 475.16 ± 4.88b 137.74 ± 3.00bc    0.0008 
15 480.82 ± 2.19ª 496.67 ± 1.68b 179.06 ± 2.27c    0.0001 
45 595.56 ± 3.17a 557.75 ± 3.65a 170.89 ± 4.25c < 0.0001 
SD ± SE: mean ± standard error of TEER-values of the Caco-2 monolayer exposed to 
OTA. Different letters (a, b, c) mean significant differences within the same exposure 
time. 
